SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

prnewswire.com - 2026-07-07 08:05:00

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FRANCISCO, Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L.

prnewswire.com - 2026-07-01 08:05:00

Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing strong Tavalisse performance and recent product acquisitions. Q1 revenues rose 10% year-over-year to $58.8 million, but net product revenues rose 26%; management also maintained FY2026 sales guidance of $275–$290 million.

seekingalpha.com - 2026-06-20 07:44:13

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions.

prnewswire.com - 2026-06-16 16:01:00

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m.

prnewswire.com - 2026-05-27 08:05:00

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO ® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster session Real-world data further supports the use of REZLIDHIA ®  (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclax SOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) will be presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, May 29, 2026.

prnewswire.com - 2026-05-21 17:17:00

SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m.

prnewswire.com - 2026-05-14 08:05:00

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

seekingalpha.com - 2026-05-12 23:10:43

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).

benzinga.com - 2026-05-12 14:38:28

VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Pivotal Phase 3 VERITAC-2 clinical trial results showed that vepdegestrant was generally well tolerated and reported mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement, in patients with 2L+ ER+/HER2- mBC with an ESR1 mutation Upon closing of the transaction, VEPPANU will become Rigel's fourth commercial product and its major focus to accelerate revenue growth while leveraging the company's existing infrastructure, contributing meaningfully to the advancement of Rigel's transformational growth strategy Arvinas and Pfizer will receive an upfront $70.0 million and an additional $15.0 million upon the successful completion of certain transition activities, and are eligible for up to $320.0 million in future potential regulatory and commercial milestones  Rigel to host a conference call today at 8:00 a.m.

prnewswire.com - 2026-05-12 07:00:00

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 07:51:14

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.63 per share a year ago.

zacks.com - 2026-05-05 19:10:40

First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million Generated $8.7 million of net income in the first quarter of 2026 On track to complete enrollment in the dose expansion phase of the Phase 1b study evaluating R289 and select the recommended Phase 2 dose in the second half of 2026 2026 Outlook: Total revenues of approximately $275 to $290 million, which includes net product sales of $255 to $265 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

prnewswire.com - 2026-05-05 16:01:00

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-28 11:06:46

SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026.

prnewswire.com - 2026-04-28 08:05:00

Investors need to pay close attention to RIGL stock based on the movements in the options market lately.

zacks.com - 2026-04-24 09:36:15